Track 03 of 9
Multiple Sclerosis
BTK inhibitors, remyelination and progressive MS.
The MS pipeline is converging on the central goal of halting smoldering, compartmentalized CNS inflammation that drives progression independent of relapse activity (PIRA). GCNN 2027 will review head-to-head data on anti-CD20 therapies (ocrelizumab, ofatumumab, ublituximab) and the maturing BTK inhibitor class — tolebrutinib (GEMINI, HERCULES), evobrutinib, fenebrutinib and remibrutinib — which uniquely penetrate the CNS to target microglia and B cells. The track also covers EBV as a causal driver, remyelination strategies, and the role of serum neurofilament light and GFAP as routine monitoring biomarkers.
Focus areas
- BTK inhibitors in MS: tolebrutinib HERCULES, evobrutinib, fenebrutinib
- Anti-CD20 therapies: ocrelizumab, ofatumumab, ublituximab subcutaneous
- Progression independent of relapse activity (PIRA) and smoldering MS
- Remyelination strategies: clemastine, elezanumab, anti-LINGO-1
- EBV as a causal driver and EBV-directed T-cell therapies
- Serum neurofilament light and GFAP as monitoring biomarkers
- High-efficacy first vs escalation: DELIVER-MS, TREAT-MS